Working Together to Find a Cure     Print Page | Close Window

2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015

July 18, 2017: Abeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis Bullosa

June 29, 2017: Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-201 Juvenile Batten Disease Gene Therapy Program

June 2, 2017: Abeona Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference

May 30, 2017: Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

May 25, 2017: Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

May 19, 2017: Abeona Therapeutics to Present at Multiple Upcoming Conferences

May 16, 2017: Abeona Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Highlights

May 12, 2017: Abeona Therapeutics Announces Top-Line Data for ABO-102 Phase 1/2 MPS IIIA Gene Therapy Trial at ASGCT

May 9, 2017: Abeona Therapeutics Receives Regulatory Approval to Initiate Clinical Trial in Australia with ABO-102 Gene Therapy For Patients with MPS IIIA

May 8, 2017: Abeona Therapeutics Announces Gene Therapy Clinical Trial and Preclinical Program Presentations at ASGCT 20th Annual Meeting

May 2, 2017: Abeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosa from the Society for Investigative Dermatology Conference

April 25, 2017: Abeona Therapeutics Announces EB-101 Clinical Update to be Presented at the Society for Investigative Dermatology Annual Meeting

April 20, 2017: Abeona to Present At Multiple Upcoming Conferences

April 5, 2017: Abeona Announces Rare Disease Gene Therapy Symposium with the New York Academy of Sciences

March 31, 2017: Abeona Therapeutics Reports Q4 2016 Financial Results and Business Highlights

March 13, 2017: Abeona Therapeutics to Present at Multiple Upcoming Investor Conferences

March 8, 2017: Abeona Therapeutics Receives Orphan Drug Designation in the European Union for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa

March 7, 2017: Abeona Therapeutics To Present At The Cowen and Company 37th Annual Health Care Conference

March 3, 2017: Abeona Therapeutics to Present at Maxim Group LLC Biotech Investor & Partnering Conference in Shanghai

February 23, 2017: Abeona Therapeutics Announces Dismissal of Securities Class Action Lawsuit

February 21, 2017: Abeona Therapeutics to Present at the 2017 RBC Capital Markets Global Healthcare Conference and 3rd Annual CRISPR Congress

February 17, 2017: Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at the 13th Annual WORLDSymposium™ 2017

February 7, 2017: Abeona Therapeutics Announces Presentations and Posters at the 13th Annual WORLDSymposium™ 2017

February 1, 2017: Abeona Therapeutics Enrolls First High Dose Subject in Ongoing Phase 1/2 Gene Therapy Clinical Trial in Sanfilippo Syndrome Type A

January 19, 2017: Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-101 Gene Therapy in Sanfilippo Syndrome Type B

January 17, 2017: Abeona Therapeutics to Present at Phacilitate Cell & Gene Therapy World 2017

January 3, 2017: Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-201 Gene Therapy Program in Juvenile Batten Disease